[Form 4] Vaxcyte, Inc. Insider Trading Activity
Insider transaction at Vaxcyte, Inc. (PCVX): The reporting person, Andrew Guggenhime (President and CFO), recorded a disposition of 2,890 shares of Vaxcyte common stock on 09/08/2025 at a price of $32.41 per share. After the transaction, Mr. Guggenhime beneficially owned 124,309 shares. The filing explains these shares were surrendered to the issuer to cover applicable tax withholding obligations arising when restricted stock units vested, indicating the transfer was related to tax withholding rather than an open-market sale. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Operazione interna in Vaxcyte, Inc. (PCVX): La persona che ha effettuato la segnalazione, Andrew Guggenhime (Presidente e CFO), ha registrato la cessione di 2.890 azioni ordinarie Vaxcyte in data 09/08/2025 al prezzo di $32,41 per azione. Dopo la transazione, il sig. Guggenhime deteneva beneficiariamente 124.309 azioni. La comunicazione precisa che le azioni sono state consegnate all'emittente per coprire le ritenute fiscali dovute al momento della maturazione delle restricted stock units, indicando quindi che il trasferimento era relativo a obblighi fiscali e non a una vendita sul mercato aperto. Il Modulo 4 è stato firmato da un procuratore delegato per conto del soggetto che ha segnalato.
Operación interna en Vaxcyte, Inc. (PCVX): La persona informante, Andrew Guggenhime (Presidente y CFO), registró una disposición de 2.890 acciones ordinarias de Vaxcyte el 09/08/2025 a un precio de $32,41 por acción. Tras la transacción, el Sr. Guggenhime poseía beneficiariamente 124.309 acciones. La presentación aclara que estas acciones se entregaron al emisor para cubrir las obligaciones fiscales aplicables derivadas del vencimiento de unidades restringidas de acciones, lo que indica que la transferencia estuvo relacionada con la retención fiscal y no con una venta en el mercado abierto. El Formulario 4 fue firmado por un apoderado en nombre de la persona informante.
Vaxcyte, Inc. (PCVX) 내부 거래: 보고인인 Andrew Guggenhime(사장 겸 CFO)는 2025-09-08에 Vaxcyte 보통주 2,890주를 주당 $32.41에 처분한 것으로 기록했습니다. 거래 후 Guggenhime 씨는 124,309주를 실질 보유하고 있었습니다. 제출 서류는 이 주식들이 제한주(RSU) 취득 시 발생한 세금 원천징수 의무를 충당하기 위해 발행사에 양도되었음을 설명하며, 이는 공개시장 판매가 아닌 세금 원천징수 관련 이전이었음을 나타냅니다. Form 4는 보고인을 대신해 법적 대리인이 서명했습니다.
Transaction d'initié chez Vaxcyte, Inc. (PCVX): La personne déclarant, Andrew Guggenhime (Président et CFO), a enregistré une cession de 2 890 actions ordinaires Vaxcyte le 09/08/2025 au prix de 32,41 $ par action. Après la transaction, M. Guggenhime détenait à titre bénéficiaire 124 309 actions. le dépôt indique que ces actions ont été remises à l'émetteur pour couvrir les obligations de retenue d'impôt applicables liées à la maturation des restricted stock units, ce qui signifie que le transfert concernait la retenue fiscale et non une vente sur le marché libre. Le formulaire 4 a été signé par un mandataire au nom de la personne déclarante.
Insider-Transaktion bei Vaxcyte, Inc. (PCVX): Die meldende Person, Andrew Guggenhime (Präsident und CFO), verzeichnete eine Veräußerung von 2.890 Vaxcyte-Stammaktien am 09/08/2025 zu einem Preis von $32,41 je Aktie. Nach der Transaktion besaß Herr Guggenhime wirtschaftlich 124.309 Aktien. Die Meldung erklärt, dass diese Aktien dem Emittenten zur Begleichung fälliger Steuerabzugsverpflichtungen im Zusammenhang mit der Vesting von Restricted Stock Units übergeben wurden, was darauf hinweist, dass die Übertragung der Steuerabführung und nicht einem Börsenverkauf diente. Das Formular 4 wurde im Namen der meldenden Person von einem Bevollmächtigten unterzeichnet.
- Disposition was for tax withholding related to RSU vesting, indicating an administrative settlement rather than an opportunistic open-market sale
- Reporting person remains materially invested with 124,309 shares beneficially owned after the transaction
- 2,890 shares were disposed, which reduced the reporting person's free shares, though purpose was tax withholding
- Filing lacks context about total outstanding shares or prior transaction patterns to assess materiality
Insights
TL;DR: Routine tax-withholding share surrender by a senior officer; not a clear signal of changed company outlook.
The reported disposition of 2,890 shares at $32.41 appears to have been executed to satisfy tax withholding obligations tied to RSU vesting rather than an opportunistic cash sale. Such actions are common for executives receiving equity compensation and typically reflect normal compensation mechanics. The remaining beneficial ownership of 124,309 shares maintains meaningful alignment with shareholders, though materiality relative to total outstanding shares is not disclosed in this filing.
TL;DR: Transaction is administrative; no evident material impact on investor valuation from this Form 4 alone.
The Form 4 shows a single-line disposition coded as related to tax withholding. The per-share price of $32.41 is reported but the filing does not indicate open-market selling or a change in trading plan. Without additional context on outstanding share count or a pattern of sales, this isolated surrender tied to RSU vesting should be viewed as routine compensation settlement rather than a directional insider trade.
Operazione interna in Vaxcyte, Inc. (PCVX): La persona che ha effettuato la segnalazione, Andrew Guggenhime (Presidente e CFO), ha registrato la cessione di 2.890 azioni ordinarie Vaxcyte in data 09/08/2025 al prezzo di $32,41 per azione. Dopo la transazione, il sig. Guggenhime deteneva beneficiariamente 124.309 azioni. La comunicazione precisa che le azioni sono state consegnate all'emittente per coprire le ritenute fiscali dovute al momento della maturazione delle restricted stock units, indicando quindi che il trasferimento era relativo a obblighi fiscali e non a una vendita sul mercato aperto. Il Modulo 4 è stato firmato da un procuratore delegato per conto del soggetto che ha segnalato.
Operación interna en Vaxcyte, Inc. (PCVX): La persona informante, Andrew Guggenhime (Presidente y CFO), registró una disposición de 2.890 acciones ordinarias de Vaxcyte el 09/08/2025 a un precio de $32,41 por acción. Tras la transacción, el Sr. Guggenhime poseía beneficiariamente 124.309 acciones. La presentación aclara que estas acciones se entregaron al emisor para cubrir las obligaciones fiscales aplicables derivadas del vencimiento de unidades restringidas de acciones, lo que indica que la transferencia estuvo relacionada con la retención fiscal y no con una venta en el mercado abierto. El Formulario 4 fue firmado por un apoderado en nombre de la persona informante.
Vaxcyte, Inc. (PCVX) 내부 거래: 보고인인 Andrew Guggenhime(사장 겸 CFO)는 2025-09-08에 Vaxcyte 보통주 2,890주를 주당 $32.41에 처분한 것으로 기록했습니다. 거래 후 Guggenhime 씨는 124,309주를 실질 보유하고 있었습니다. 제출 서류는 이 주식들이 제한주(RSU) 취득 시 발생한 세금 원천징수 의무를 충당하기 위해 발행사에 양도되었음을 설명하며, 이는 공개시장 판매가 아닌 세금 원천징수 관련 이전이었음을 나타냅니다. Form 4는 보고인을 대신해 법적 대리인이 서명했습니다.
Transaction d'initié chez Vaxcyte, Inc. (PCVX): La personne déclarant, Andrew Guggenhime (Président et CFO), a enregistré une cession de 2 890 actions ordinaires Vaxcyte le 09/08/2025 au prix de 32,41 $ par action. Après la transaction, M. Guggenhime détenait à titre bénéficiaire 124 309 actions. le dépôt indique que ces actions ont été remises à l'émetteur pour couvrir les obligations de retenue d'impôt applicables liées à la maturation des restricted stock units, ce qui signifie que le transfert concernait la retenue fiscale et non une vente sur le marché libre. Le formulaire 4 a été signé par un mandataire au nom de la personne déclarante.
Insider-Transaktion bei Vaxcyte, Inc. (PCVX): Die meldende Person, Andrew Guggenhime (Präsident und CFO), verzeichnete eine Veräußerung von 2.890 Vaxcyte-Stammaktien am 09/08/2025 zu einem Preis von $32,41 je Aktie. Nach der Transaktion besaß Herr Guggenhime wirtschaftlich 124.309 Aktien. Die Meldung erklärt, dass diese Aktien dem Emittenten zur Begleichung fälliger Steuerabzugsverpflichtungen im Zusammenhang mit der Vesting von Restricted Stock Units übergeben wurden, was darauf hinweist, dass die Übertragung der Steuerabführung und nicht einem Börsenverkauf diente. Das Formular 4 wurde im Namen der meldenden Person von einem Bevollmächtigten unterzeichnet.
FAQ
What did Andrew Guggenhime report on Form 4 for PCVX?
Why were the 2,890 PCVX shares disposed of?
Did the Form 4 indicate an open-market sale for PCVX shares?
How much was the reported per-share price on the transaction?
Who signed the Form 4 for the reporting person?
